"Rifampin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)
MeSH Number(s)
D03.549.811.700
D04.345.295.750.700
Below are MeSH descriptors whose meaning is more general than "Rifampin".
Below are MeSH descriptors whose meaning is more specific than "Rifampin".
This graph shows the total number of publications written about "Rifampin" by people in Harvard Catalyst Profiles by year, and whether "Rifampin" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 1 | 0 | 1 |
| 1994 | 2 | 1 | 3 |
| 1996 | 1 | 1 | 2 |
| 1997 | 1 | 1 | 2 |
| 1998 | 4 | 1 | 5 |
| 2001 | 2 | 1 | 3 |
| 2002 | 1 | 1 | 2 |
| 2003 | 0 | 5 | 5 |
| 2004 | 3 | 4 | 7 |
| 2005 | 1 | 6 | 7 |
| 2006 | 0 | 6 | 6 |
| 2007 | 1 | 1 | 2 |
| 2008 | 1 | 1 | 2 |
| 2009 | 0 | 3 | 3 |
| 2010 | 0 | 2 | 2 |
| 2011 | 5 | 7 | 12 |
| 2012 | 4 | 5 | 9 |
| 2013 | 1 | 4 | 5 |
| 2014 | 6 | 4 | 10 |
| 2015 | 0 | 4 | 4 |
| 2016 | 5 | 6 | 11 |
| 2017 | 8 | 6 | 14 |
| 2018 | 5 | 10 | 15 |
| 2019 | 8 | 9 | 17 |
| 2020 | 3 | 11 | 14 |
| 2021 | 6 | 15 | 21 |
| 2022 | 2 | 10 | 12 |
| 2023 | 0 | 1 | 1 |
Below are the most recent publications written about "Rifampin" by people in Profiles.
-
Concordance of three approaches for operationalizing outcome definitions for multidrug-resistant TB. Int J Tuberc Lung Dis. 2023 Jan 01; 27(1):34-40.
-
Low Body Mass Index at Treatment Initiation and Rifampicin-Resistant Tuberculosis Treatment Outcomes: An Individual Participant Data Meta-Analysis. Clin Infect Dis. 2022 12 19; 75(12):2201-2210.
-
Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs. Clin Infect Dis. 2022 10 12; 75(8):1307-1314.
-
Household contact management for rifampicin-resistant tuberculosis. Lancet Glob Health. 2022 10; 10(10):e1387.
-
Pediatric delamanid treatment for children with rifampicin-resistant TB. Int J Tuberc Lung Dis. 2022 10 01; 26(10):986-988.
-
Population Pharmacokinetic Modeling and Simulation of Rifapentine Supports Concomitant Antiretroviral Therapy with Efavirenz and Non-Weight Based Dosing. Antimicrob Agents Chemother. 2022 09 20; 66(9):e0238521.
-
A Case Series of Rifabutin Use in Staphylococcal Prosthetic Infections. Microbiol Spectr. 2022 06 29; 10(3):e0038422.
-
Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women. Clin Infect Dis. 2022 05 03; 74(9):1604-1613.
-
High Prevalence of Tuberculosis Infection and Disease in Child Household Contacts of Adults With Rifampin-resistant Tuberculosis. Pediatr Infect Dis J. 2022 05 01; 41(5):e194-e202.
-
Whole-Genome Sequencing Has the Potential To Improve Treatment for Rifampicin-Resistant Tuberculosis in High-Burden Settings: a Retrospective Cohort Study. J Clin Microbiol. 2022 03 16; 60(3):e0236221.